Data collection within patient support programs in Canada and implications for real-world evidence generation: the authors' perspective

This article illustrates the current state of PSP data collection by examining six PSP RWE studies and outlining their data characteristics and the health outcomes collected from the PSP. A framework for collecting real-world data within a PSP and a checklist to address issues of trust and bias in PSP data collection is also provided. Collaboration between drug manufacturers, PSP vendors, and data specialists will be crucial in elevating PSP data to a level acceptable to healthcare decision makers, including health technology assessors and payers, with the ultimate beneficiary being patients.PMID:37901362 | PMC:PMC10603246 | DOI:10.3389/jpps.2023.11877
Source: J Pharm Pharm Sci - Category: Drugs & Pharmacology Authors: Source Type: research